SKYCLARYS (omaveloxolone) by Biogen is cytochrome p450 3a4 inducers [moa]. First approved in 2023.
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
SKYCLARYS (omaveloxolone) is an oral small-molecule cytochrome P450 3A4 inducer approved in February 2023 for Friedreich's ataxia, a rare inherited neurological disorder. The drug works by activating cellular stress response pathways to reduce oxidative damage and neuroinflammation in affected tissues.
Early-stage product in peak growth phase with strong Biogen backing; commercial team expansion likely as market penetration increases.
Cytochrome P450 3A4 Inducers
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55
A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55
A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
Worked on SKYCLARYS at Biogen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moSKYCLARYS offers 241 linked career opportunities with strong demand across commercial, finance, and medical affairs functions. Working on this rare disease product provides exposure to specialty pharma operations, payer negotiation, and orphan drug commercialization strategies.
241 open roles linked to this drug